专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09630444B2 Rotating-operation type of writing tool 有权
公开(公告)号：US09630444B2
公开(公告)日：2017-04-25
申请号：US14430880
申请日：2013-09-20
申请人： Kabushiki Kaisha Pilot Corporation
发明人： Masaaki Kubota
IPC分类号： B43K7/12 , B43K24/06 , B43K8/24 , B43K5/16 , B43K5/17 , F16H25/18
CPC分类号： B43K24/06 , B43K5/16 , B43K5/17 , B43K7/12 , B43K8/24 , F16H25/186 , Y10T74/18568
摘要： When the rear axial cylinder (3) is rotated, the cam cylinder (17) is also rotated, thereby the cam protrusion (18a) moves forward by means of the functions of the cam groove (17a) and the slit (18b), so that the slider (18) moves forward to cause the writing body (14) to move forward against a biasing force by the biasing member (15). The cam cylinder (17) and the rear axial cylinder (3) are fixed via the adjustment mechanism of rotational positions (17n).

2. 发明授权

US09417246B2 Insulin receptor substrate 1 (IRS1) protein SRM/MRM assay 有权
标题翻译：胰岛素受体底物1（IRS1）蛋白SRM / MRM测定
公开(公告)号：US09417246B2
公开(公告)日：2016-08-16
申请号：US13529902
申请日：2012-06-21
申请人： David B. Krizman , Todd Hembrough , Sheeno Thyparambil
发明人： David B. Krizman , Todd Hembrough , Sheeno Thyparambil
IPC分类号： C12Q1/37 , G01N33/68
CPC分类号： G01N33/57496 , G01N33/574 , G01N33/6848 , G01N2333/4703 , G01N2333/62 , G01N2333/72 , G01N2440/14 , G01N2440/38 , G01N2560/00 , G01N2800/52
摘要： The current disclosure provides for specific peptides from the Insulin Receptor Substrate 1 (IRS1) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying IRS1 directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. IRS1 protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of IRS1 peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
摘要翻译：目前的公开内容提供了来自胰岛素受体底物1（IRS1）蛋白的特异性肽和这些肽的衍生电离特征，其有利于通过选择反应监测（SRM）质谱法直接定量福尔马林固定生物样品中的IRS1。这样的固定生物样品包括：福尔马林固定的组织/细胞，福尔马林固定/石蜡包埋（FFPE）组织/细胞，FFPE组织块和来自那些块的细胞，以及福尔马林固定和石蜡包埋的组织培养细胞。通过定量本文所述的一种或多种肽，通过SRM / MRM质谱法测定生物样品中的IRS1蛋白质。如果它们以修饰或未修饰的形式存在，则可定量肽。 IRS1肽的潜在修饰形式的实例包括在肽序列内具有酪氨酸，苏氨酸，丝氨酸和/或其它氨基酸残基磷酸化的那些。

3. 发明授权

US09274124B2 Mass spectrometric assays for peptides 有权
标题翻译：肽的质谱测定
公开(公告)号：US09274124B2
公开(公告)日：2016-03-01
申请号：US13635668
申请日：2011-03-15
申请人： Norman Leigh Anderson
发明人： Norman Leigh Anderson
IPC分类号： C40B30/10 , G01N33/68 , G01N30/72 , G01N30/04 , G01N30/88
CPC分类号： G01N33/6851 , C07K7/06 , C07K7/08 , C07K17/06 , C12Y304/21004 , G01N27/62 , G01N30/7233 , G01N33/6848 , G01N2030/045 , G01N2030/8831 , G01N2333/976 , G01N2458/15 , G01N2496/00 , G01N2560/00
摘要： Methods for interpretation of mass spectrometric tests for clinical biomarkers in which the amounts of internal standards are set to equal clinical evaluation thresholds, and preparations for adding stable isotope labeled peptide species to sample digests while minimizing losses and alterations in peptide stoichiometry.
摘要翻译：用于解释临床生物标志物的质谱检测方法，其中将内标物质量设定为等同于临床评估阈值，以及将稳定同位素标记的肽物质添加到样品消化中同时最小化肽化学计量学的损失和改变的制备方法。

4. 发明授权

US09163275B2 Liquid tissue preparation from histopathologically processed biologically samples, tissues and cells 有权
标题翻译：来自组织病理学处理的生物样品，组织和细胞的液体组织制备
公开(公告)号：US09163275B2
公开(公告)日：2015-10-20
申请号：US13896778
申请日：2013-05-17
申请人： Expression Pathology, Inc.
发明人： Marlene M. Darfler , David B. Krizman
IPC分类号： C12Q1/68 , C12M3/00 , G01N33/53 , C12Q1/37 , C12N15/10 , G01N1/44 , C40B30/04 , C40B40/06 , C40B40/08 , G01N1/30 , G01N1/40
CPC分类号： G01N1/4044 , C12N15/1003 , C12Q1/37 , G01N1/30 , G01N1/44
摘要： The current invention provides a method for directly converting histopathologically processed biological samples, tissues, and cells into a multi-use biomolecule lysate. This method allows for simultaneous extraction, isolation, solublization, and storage of all biomolecules contained within the histopathologically processed biological sample, thereby forming a representative library of said sample. This multi-use biomolecule lysate is dilutable, soluble, capable of being fractionated, and used in any number of subsequent experiments.
摘要翻译：本发明提供了一种将组织病理学处理的生物样品，组织和细胞直接转化成多用途生物分子裂解物的方法。该方法允许同时提取，分离，溶解和储存包含在组织病理学处理的生物样品中的所有生物分子，从而形成所述样品的代表性文库。这种多用途生物分子裂解物是可稀释的，可溶的，能够分级，并用于任何数量的后续实验。

5. 发明授权

US09128102B2 Her3 protein SRM/MRM assay 有权
标题翻译： Her3蛋白SRM / MRM检测
公开(公告)号：US09128102B2
公开(公告)日：2015-09-08
申请号：US13932883
申请日：2013-07-01
申请人： David Krizman , Todd Hembrough , Sheeno Thyparambil
发明人： David Krizman , Todd Hembrough , Sheeno Thyparambil
IPC分类号： G01N30/72 , G01N33/68 , G01N33/574 , G01N33/74
CPC分类号： G01N33/6848 , G01N33/574 , G01N33/6893 , G01N33/74 , G01N2333/485 , G01N2333/71 , G01N2333/912 , G01N2333/9121
摘要： The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the Receptor Tyrosine-Protein Kinase erbB-3, or Her3, that are particularly advantageous for quantifying the Her3 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from said biological sample using the Liquid Tissue™ reagents and protocol and the Her3 protein is quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of a Her3 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
摘要翻译：目前的公开内容提供了来自受体酪氨酸 - 蛋白激酶erbB-3或Her3的肽的特定肽和衍生的电离特征，其特别有利于直接在通过福尔马林固定的福尔马林生物样品中定量Her3蛋白选择反应监测（SRM）质谱法的方法，或称为多反应监测（MRM）质谱的方法。这样的生物样品被化学保存和固定，其中所述生物样品选自用含甲醛的试剂/固定剂（包括福尔马林固定的组织/细胞，福尔马林固定/石蜡包埋的（FFPE）组织/细胞，FFPE组织块）和来自这些区块的细胞和已被福尔马林固定和石蜡包埋的组织培养细胞。使用Liquid Tissue TM试剂和方案从所述生物样品制备蛋白质样品，并且通过SRM / MRM质谱法的方法在Liquid Tissue TM样品中定量Her3蛋白质，通过在蛋白质样品中定量至少一种或多种描述的肽。如果它们以修饰或未修饰的形式存在，则可以定量这些肽。 Her3肽的修饰形式的实例是肽序列内的酪氨酸，苏氨酸，丝氨酸和/或其他氨基酸残基的磷酸化。

6. 发明授权

US09095568B2 Therapeutic and vaccine polyelectrolyte nanoparticle compositions 有权
标题翻译：治疗和疫苗聚电解质纳米颗粒组合物
公开(公告)号：US09095568B2
公开(公告)日：2015-08-04
申请号：US12680548
申请日：2008-09-26
申请人： Mark Berninger , Puthupparampil Scaria
发明人： Mark Berninger , Puthupparampil Scaria
IPC分类号： A61K39/07 , A61K39/00 , A61K39/385 , A61K47/00 , A01N63/00 , A61K39/39
CPC分类号： A61K47/48907 , A61K31/575 , A61K39/07 , A61K39/39 , A61K47/6455 , A61K47/6935 , A61K2039/55555 , A61K2039/6093 , C08G63/91
摘要： Polyelectrolyte nanoparticle compositions for biomedical applications are provided comprising at least two carrier domains comprising multivalent ionic domains and an agent exhibiting biological activity when contained within the nanoparticle or on the nanoparticle surface. The multivalent ionic domains may be contained in two separate molecules or in separate but linked domains of a single molecule. The nanoparticle optionally can further comprise an exposed targeting ligand and/or protective surface. The nanoparticle can be contacted to cells or administered directly to an animal for biomedical applications including therapeutics and immune response. The nanoparticle may alternatively be comprised of a carrier material capable of delivering various medically important antigens as vaccine.
摘要翻译：提供了用于生物医学应用的聚电解质纳米颗粒组合物，其包含至少两个包含多价离子结构域的载体结构域和当纳入纳米颗粒或纳米颗粒表面时含有生物活性的试剂。多价离子结构域可以包含在两个分开的分子中或者在单个分子的单独但连接的结构域中。纳米颗粒任选地还可以包含暴露的靶向配体和/或保护表面。纳米颗粒可以与细胞接触或直接施用于动物用于生物医学应用，包括治疗学和免疫应答。纳米颗粒可以替代地由能够递送各种医学上重要的抗原作为疫苗的载体材料组成。

7. 发明授权

US08308901B2 Enhanced fiber additive; and use 有权
公开(公告)号：US08308901B2
公开(公告)日：2012-11-13
申请号：US12903707
申请日：2010-10-13
申请人： Kevin R. Anderson , David E. Garlie , Paula R. Krogmann , John T. McDonald , Jagannadh V. Satyavolu
发明人： Kevin R. Anderson , David E. Garlie , Paula R. Krogmann , John T. McDonald , Jagannadh V. Satyavolu
IPC分类号： D21H11/12 , D21H11/14 , D21H11/16
CPC分类号： D21H17/02 , A21D2/188 , A23L7/115 , A23L13/426 , A23L33/24 , C08B30/10 , C08L5/14 , D01C1/02 , D06L4/13 , D21C3/04 , D21C3/12 , D21C5/00 , D21H11/12 , D21H11/20 , D21H21/52
摘要： The disclosure provides a process of modifying a seed based fiber (SBF) to form an enhanced fiber additive (EFA). The process includes an acid treatment step and optionally at least one fiber modification step. Preferred EFA products and uses are described.

8. 发明授权

US07451196B1 Method and system for executing a software application in a virtual environment 有权
标题翻译：在虚拟环境中执行软件应用程序的方法和系统
公开(公告)号：US07451196B1
公开(公告)日：2008-11-11
申请号：US10023915
申请日：2001-12-14
申请人： Jeffrey de Vries , Gregory Zavertnik
发明人： Jeffrey de Vries , Gregory Zavertnik
IPC分类号： G06F15/177 , G06F15/16
CPC分类号： H04L67/34 , G06F8/61 , G06F9/544 , G06F9/545 , G06F2209/542 , H04L67/40
摘要： Method and system for executing a software application in a virtual environment includes a file system hook operatively interposed between a file system manager and a file system driver of the local computer, the file system hook configured to detect a file system call corresponding to a target program and to perform one or more procedures, and an agent procedure executing on the local computer to configure the file system hook for executing the target program. Also provided is a token file corresponding to the target program, the token file including file system overlay information for the target program. The one or more procedures may include accessing data at a server terminal operatively coupled to the local computer via a data network, or at a locally connected CD-ROM drive. Numerous other aspects are provided.
摘要翻译：用于在虚拟环境中执行软件应用的方法和系统包括可操作地插入在文件系统管理器和本地计算机的文件系统驱动器之间的文件系统钩子，所述文件系统钩子被配置为检测对应于目标程序的文件系统调用并执行一个或多个过程，以及在本地计算机上执行的代理程序来配置用于执行目标程序的文件系统钩。还提供了与目标程序相对应的令牌文件，令牌文件包括目标程序的文件系统覆盖信息。该一个或多个过程可以包括经由数据网络或本地连接的CD-ROM驱动器访问可操作地耦合到本地计算机的服务器终端处的数据。提供了许多其他方面。

9. 发明授权

US09233952B2 Compositions and methods for inhibiting cytochrome P450 有权
公开(公告)号：US09233952B2
公开(公告)日：2016-01-12
申请号：US13937985
申请日：2013-07-09
申请人： SEQUOIA PHARMACEUTICALS, INC.
发明人： Michael Eissenstat , Dehui Duan
IPC分类号： A61K31/343 , C07D405/14 , A61K31/33 , A61K31/4155 , A61K31/4178 , A61K31/4184 , A61K31/4196 , A61K31/427 , A61K31/4427 , A61K31/4709 , A61K45/06 , A61K31/437 , A61K31/4433 , A61K31/4545 , C07D307/79 , C07D405/12 , C07D417/12 , C07D471/04 , C07D491/048
CPC分类号： A61K31/343 , A61K31/33 , A61K31/4155 , A61K31/4178 , A61K31/4184 , A61K31/4196 , A61K31/427 , A61K31/437 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K45/06 , C07D307/79 , C07D405/12 , C07D405/14 , C07D417/12 , C07D471/04 , C07D491/048 , A61K2300/00
摘要： Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.

10. 发明授权

US07981929B2 Benzofuran derived HIV protease inhibitors 有权
标题翻译：苯并呋喃衍生的HIV蛋白酶抑制剂
公开(公告)号：US07981929B2
公开(公告)日：2011-07-19
申请号：US12050125
申请日：2008-03-17
申请人： Michael Eissenstat
发明人： Michael Eissenstat
IPC分类号： A61K31/343 , C07D307/78 , C07D407/12
CPC分类号： C07D493/04
摘要： Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.
摘要翻译：提供抗驱虫和多药耐药的逆转录病毒蛋白酶抑制剂。还提供了包含这些化合物的药物组合物，以及使用这些化合物治疗哺乳动物HIV感染的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式